Suchergebnisse - "Trotter, James F."

1

Outcomes Among Living Liver Donors

von: Trotter, James F.

2012, in: Gastroenterology

Wird geladen...
2

Preoperative transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic patients undergoing abdominal and pelvic surgeries

von: Schlenker, Christine

2009, in: Surgical endoscopy and other interventional techniques

Wird geladen...
3

HBIg Discontinuation with Maintenance Oral Anti-viral Therapy and HBV Vaccination in Liver Transplant Recipients

von: Weber, Nicholas K.

2009, in: Digestive diseases and sciences

Wird geladen...
4

Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS Database

von: Goldberg, David S.

2014, in: Ubiquitin protease Ubp8 is necessary for

Wird geladen...
5

Prospective multicenter study of sofosbuvir-velpatasvir (SOF/VEL) in hepatitis C virus (HCV) negative liver (LT) and kidney transplant (KT) recipients receiving HCV viremic donors

von: Rubin, Raymond

2020, in: Identification of the antigenic region of

Wird geladen...
6

The FGF19 analogue aldafermin improves non-invasive tests in patients with non-alcoholic steatohepatitis

von: Ryan, Marno

2020, in: Identification of the antigenic region of

Wird geladen...
7

Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients

von: Harrison, Stephen

2020, in: Identification of the antigenic region of

Wird geladen...
8

Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse

von: Gottlieb, Robert L.

2017, in: Investigating polyethersulfone interleaved Glass/Carbon hybrid composite under impact and its comparison with GLARE

Wird geladen...
9

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

von: Rinella, Mary E.

2018, in: Journal of hepatology

Wird geladen...
10

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy

von: Burton, James R.

2014, in: Identification of the antigenic region of

Wird geladen...
11

Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1)

von: Loomba, Rohit

2020, in: Identification of the antigenic region of

Wird geladen...
12

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

von: Harrison, Stephen A

2018, in: Effects of shape functions on flexural–torsional buckling of fixed circular arches

Wird geladen...
13

GFR reset point at 3 months after liver transplant is a superior predictor of liver and kidney disease related outcomes: analysis from a large cohort of NASH patients (nail NASH consortium)

von: Satapathy, Sanjaya

2020, in: Identification of the antigenic region of

Wird geladen...
14

Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

von: Harrison, Stephen A.

2020, in: Identification of the antigenic region of

Wird geladen...
15

Long-term outcomes (beyond 5 years) of liver transplant recipients-a transatlantic multicentre study

von: Palaniyappan, Naaventhan

2022, in: Identification of the antigenic region of

Wird geladen...
16

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

von: Harrison, Stephen A.

2021, in: Gastroenterology

Wird geladen...
17

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

von: Hirschfield, Gideon M.

2019, in: Identification of the antigenic region of

Wird geladen...
18

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

von: Loomba, Rohit

2021, in: Ubiquitin protease Ubp8 is necessary for

Wird geladen...
19

Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study

von: Younossi, Zobair M.

2020, in: Identification of the antigenic region of

Wird geladen...
20

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

von: Sanyal, Arun J.

2023, in: Journal of hepatology

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!